MICHAEL F MAGUIRE M.D.
Prescription History 1124186721
Internal Medicine - Critical Care Medicine in Appleton, WI

NPI Status: Active since December 05, 2006

Contact Information

2500 E CAPITOL DRIVE
SUITE 1700
APPLETON, WI
ZIP 54911
Phone: (920) 734-9600
Fax: (920) 734-4773

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MICHAEL F MAGUIRE M.D., an active Critical Care Medicine specialist practicing in Appleton, WI. Our medical registry currently tracks 29 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,406 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 196 claims alone.


Adempas

Generic Formulation: RiociguatSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
WI State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills74.6
Peer Average Days Supply2,202
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.8% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $155,514.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,959.54

State Avg Cost Per Claim

$12,698.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Riociguat is used to treat high blood pressure in the lungs (pulmonary hypertension). It can also be used to treat a certain type of high blood pressure in the lungs caused by blood clots (chronic thromboembolic pulmonary hypertension) when surgery has not been fully successful or is impossible. Riociguat works by relaxing and widening the blood vessels in your lungs so blood can flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 196
30-Day Fills 274.1
Days Supply 6,489
WI State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills68.1
Peer Average Days Supply1,588
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 256.4% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,882.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.11

State Avg Cost Per Claim

$51.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 63
30-Day Fills 83.0
Days Supply 2,490
WI State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills42.6
Peer Average Days Supply1,264
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 85.3% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,770.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$631.27

State Avg Cost Per Claim

$574.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Armodafinil

Generic Formulation: ArmodafinilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
WI State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills19.7
Peer Average Days Supply569
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,211.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$93.20

State Avg Cost Per Claim

$105.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.

Therapeutic Applications

Armodafinil reduces extreme sleepiness due to narcolepsy and other sleep disorders, such as periods of stopped breathing during sleep (obstructive sleep apnea). It is also used to help you stay awake during work hours if you have a work schedule that keeps you from having a normal sleep routine (shift work sleep disorder). This medication does not cure these sleep disorders and may not get rid of all your sleepiness. Armodafinil does not take the place of getting enough sleep. It should not be used to treat tiredness or hold off sleep in people who do not have a sleep disorder. It is not known how armodafinil works to keep you awake. It is thought to work by affecting certain substances in the brain that control the sleep/wake cycle.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
WI State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills36.7
Peer Average Days Supply1,096
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,944.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$235.44

State Avg Cost Per Claim

$311.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.1
Days Supply 389
WI State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills30.3
Peer Average Days Supply349
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $164.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.34

State Avg Cost Per Claim

$12.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 112
30-Day Fills 140.0
Days Supply 4,200
WI State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills42.6
Peer Average Days Supply1,271
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 250.0% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $58,895.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$525.85

State Avg Cost Per Claim

$529.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Clonazepam

Generic Formulation: ClonazepamSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
WI State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills57.6
Peer Average Days Supply1,620
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.0% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $64.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.40

State Avg Cost Per Claim

$9.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 44.0
Days Supply 1,320
WI State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills27.7
Peer Average Days Supply806
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,637.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$595.08

State Avg Cost Per Claim

$642.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Daliresp

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 306
WI State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills40.5
Peer Average Days Supply1,170
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.1% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,686.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$668.21

State Avg Cost Per Claim

$547.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Flovent Hfa

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 62
30-Day Fills 62.0
Days Supply 1,860
WI State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills35.0
Peer Average Days Supply1,045
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 181.8% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,254.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$326.68

State Avg Cost Per Claim

$442.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 28
30-Day Fills 62.7
Days Supply 1,880
WI State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills84.1
Peer Average Days Supply2,506
Conservative Utilization

This provider writes prescriptions for this formulation 40.4% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $510.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.22

State Avg Cost Per Claim

$18.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 68
30-Day Fills 101.0
Days Supply 3,030
WI State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills34.2
Peer Average Days Supply1,024
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 195.7% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,235.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$282.87

State Avg Cost Per Claim

$250.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Glassia

Generic Formulation: Alpha-1-Proteinase InhibitorSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.3
Days Supply 330
WI State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.8
Peer Average Days Supply340
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116,052.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,671.02

State Avg Cost Per Claim

$9,128.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES.

Therapeutic Applications

This medication is used to treat lung problems (emphysema) caused by a certain inherited disease (alpha-1-proteinase inhibitor deficiency). In people with this condition, lung damage is caused by elastase, a natural substance that the body needs to kill bacteria in the lungs. Normally, a protein (alpha-1-proteinase inhibitor) stops elastase from working when it is no longer needed. However, in people who do not make enough of this protein, elastase does not stop working and damages the lungs. This medication replaces the missing alpha-1-proteinase inhibitor and helps to prevent further lung damage.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 51
30-Day Fills 57.0
Days Supply 1,710
WI State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply979
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 96.2% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,405.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$419.71

State Avg Cost Per Claim

$464.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Modafinil

Generic Formulation: ModafinilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 37.0
Days Supply 1,110
WI State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills27.7
Peer Average Days Supply815
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 31.8% more claims than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,697.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.54

State Avg Cost Per Claim

$175.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.

Therapeutic Applications

Modafinil reduces extreme sleepiness due to narcolepsy and other sleep disorders, such as periods of stopped breathing during sleep (obstructive sleep apnea). It is also used to help you stay awake during work hours if you have a work schedule that keeps you from having a normal sleep routine (shift work sleep disorder). This medication does not cure these sleep disorders and may not get rid of all your sleepiness. Modafinil does not take the place of getting enough sleep. It should not be used to treat tiredness or hold off sleep in people who do not have a sleep disorder. It is not known how modafinil works to keep you awake. It is thought to work by affecting certain substances in the brain that control the sleep/wake cycle.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 180
30-Day Fills 415.2
Days Supply 12,445
WI State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills99.1
Peer Average Days Supply2,947
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 318.6% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,633.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.63

State Avg Cost Per Claim

$18.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Nucala

Generic Formulation: MepolizumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 420
WI State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.2
Peer Average Days Supply511
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $58,596.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,906.43

State Avg Cost Per Claim

$3,676.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you do your normal activities and decreases time lost from work or school. Mepolizumab is also used to treat certain other immune system disorders (chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome). This medication works by decreasing a certain type of white blood cell (eosinophils). This effect helps reduce swelling (inflammation) of the airways to make breathing easier. It may also help reduce the size of nasal polyps, and lessen symptoms such as runny/stuffy nose, mucus in the throat, loss of smell, facial pain, and tiredness. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 720
WI State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.5
Peer Average Days Supply822
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $306,072.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,753.02

State Avg Cost Per Claim

$12,285.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 78
30-Day Fills 106.1
Days Supply 2,797
WI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills53.7
Peer Average Days Supply1,056
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 90.2% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $564.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.24

State Avg Cost Per Claim

$7.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Roflumilast

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 26.0
Days Supply 780
WI State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply654
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,172.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$135.78

State Avg Cost Per Claim

$281.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Handihaler

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 39.0
Days Supply 1,170
WI State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills38.5
Peer Average Days Supply1,142
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,715.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$714.34

State Avg Cost Per Claim

$783.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 510
WI State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills40.3
Peer Average Days Supply1,207
Conservative Utilization

This provider writes prescriptions for this formulation 43.3% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,212.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$541.90

State Avg Cost Per Claim

$676.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 34
30-Day Fills 44.0
Days Supply 1,320
WI State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills48.8
Peer Average Days Supply1,461
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,940.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$615.90

State Avg Cost Per Claim

$613.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 49
30-Day Fills 82.0
Days Supply 2,460
WI State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills45.0
Peer Average Days Supply1,349
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 53.1% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,451.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$641.86

State Avg Cost Per Claim

$527.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 92
30-Day Fills 122.0
Days Supply 3,660
WI State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills68.9
Peer Average Days Supply2,062
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 70.4% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $81,690.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$887.94

State Avg Cost Per Claim

$820.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 27.7
Days Supply 732
WI State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills28.6
Peer Average Days Supply648
Conservative Utilization

This provider writes prescriptions for this formulation 41.7% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,612.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$115.20

State Avg Cost Per Claim

$80.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 92
30-Day Fills 132.0
Days Supply 3,960
WI State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills35.5
Peer Average Days Supply1,065
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 300.0% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,419.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$308.90

State Avg Cost Per Claim

$314.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Xyrem

Generic Formulation: Sodium OxybateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
WI State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.4
Peer Average Days Supply615
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $277,102.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,473.47

State Avg Cost Per Claim

$16,259.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The sodium salt of 4-hydroxybutyric acid. It is used for both induction and maintenance of ANESTHESIA.

Therapeutic Applications

This medication is used to treat narcolepsy, a condition that causes severe daytime sleepiness. Sodium oxybate can decrease daytime sleepiness and also reduce the number of sudden short attacks of weak/paralyzed muscles (known as cataplexy) that can occur in patients with narcolepsy. Sodium oxybate is a central nervous system depressant. It is also known as gamma hydroxybutyrate (GHB).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MICHAEL F MAGUIRE M.D. provides transparency into local medical care patterns within Appleton, WI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Critical Care Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.